BPC-157
A pentadecapeptide studied in tissue repair investigation.
- Molecular weight
- 1419.5 g/mol
- Half-life
- ~30 minutes (oral, rodent)
- Research dose range
- 200-500 mcg per research subject
- Receptor targets
- VEGF, NO synthase, GH receptor crosstalk
BEFORE YOU ENTER
Please confirm each of the statements below. They form a single binding agreement. A timestamped record is kept on your device and attached to any order you place; you will not be asked to confirm again at checkout.
Kodiac biolabs sources, lyophilizes, and fulfills research peptides for serious investigators. Every batch is HPLC-verified by our supplier with documentation published in full. Independent Janoshik third-party verification is in progress. Every order ships cold-chain.

Kodiac exists because research compounds deserve laboratory rigor, not gray-market shortcuts. We source from disciplined manufacturers, verify every batch through independent HPLC analysis, and document every lot with a publicly retrievable certificate of analysis. The work the science requires is the work we do.
Nootropic of the week
COGNITIVE / Week 1 of 3
A methylsulfonyl benzoxazine ampakine that advanced furthest of the CX-series in human trials, including military sleep deprivation studies.
A pentadecapeptide studied in tissue repair investigation.
A synthetic fragment of thymosin beta-4 studied in tissue repair contexts.
A selective GHRP studied for ghrelin receptor modulation.
A GHRH analog studied without DAC modification.
A tetrapeptide bioregulator studied for telomerase activity.
We started Kodiac because the research-compound market was full of products and empty of proof.
Most vendors photograph a vial, write a tagline, and call it credibility. We took the longer route. Bulk peptide sourced from a disciplined manufacturer with full vendor HPLC, mass spectrometry, and 1H NMR documentation per lot. Independent Janoshik third-party verification is in progress and will be published alongside the existing reports as it completes. Every lot is documented, scanned, and posted publicly so investigators can verify before they buy.
That is the entire model. Source carefully. Verify independently. Document everything. Ship cold. Disclose the rest.
A structurally distinct, high-affinity CGRP receptor antagonist developed at Bristol-Myers Squibb and advanced by Biohaven, distinguished...
Read Selective ATP-competitive Rho-associated coiled-coil containing protein kinase (ROCK) inhibitorA pyridine-cyclohexanecarboxamide developed at Yoshitomi Pharmaceutical as the prototypical selective ROCK inhibitor, distinguished by br...
Read Broad-spectrum voltage-gated sodium channel blocker with state-dependent and use-dependent inhibition and secondary monoamine oxidase B inhibitory activityA pyrrolidine carboxamide sodium channel blocker developed at GlaxoSmithKline and advanced through Convergence Pharmaceuticals and Biogen...
Read